NASDAQ:NTLA - Intellia Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $146.28
  • Forecasted Upside: 29.30 %
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 15 Buy Ratings
  • 0 Strong Buy Ratings
▼ -2.39 (-2.07%)

This chart shows the closing price for NTLA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Intellia Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NTLA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTLA

Analyst Price Target is $146.28
▲ +29.30% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $146.28, with a high forecast of $252.00 and a low forecast of $52.00. The average price target represents a 29.30% upside from the last price of $113.13.

This chart shows the closing price for NTLA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 18 investment analysts is to buy stock in Intellia Therapeutics. This rating has held steady since July 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 15 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/5/2021OppenheimerLower Price TargetMarket Perform$160.00 ➝ $145.00Low
11/5/2021HC WainwrightBoost Price TargetBuy$171.00 ➝ $182.00Medium
10/21/2021HC WainwrightReiterated RatingBuy$172.00Medium
10/5/2021GuggenheimInitiated CoverageBuy$170.00Low
9/23/2021Stifel NicolausInitiated CoverageBuy$173.00High
9/16/2021Chardan CapitalReiterated RatingBuy$177.00Low
9/13/2021HC WainwrightReiterated RatingBuy$171.00Medium
8/6/2021JMP SecuritiesBoost Price TargetMarket Outperform$160.00 ➝ $175.00Medium
8/6/2021The Goldman Sachs GroupBoost Price TargetBuy$225.00 ➝ $252.00Medium
8/6/2021OppenheimerBoost Price TargetMarket Perform$125.00 ➝ $160.00Medium
8/6/2021Chardan CapitalBoost Price TargetBuy$130.00 ➝ $177.00Low
8/6/2021Raymond JamesBoost Price TargetOutperform$168.00 ➝ $181.00Low
8/5/2021Roth CapitalBoost Price TargetBuy$110.00 ➝ $180.00Medium
7/7/2021Chardan CapitalReiterated RatingBuyMedium
7/1/2021Robert W. BairdReiterated RatingHold$85.00High
6/29/2021OppenheimerBoost Price TargetMarket Perform$73.00 ➝ $125.00High
6/29/2021Raymond JamesBoost Price TargetOutperform$106.00 ➝ $168.00High
6/28/2021Royal Bank of CanadaBoost Price TargetOutperform$110.00 ➝ $150.00High
6/28/2021TruistBoost Price TargetBuy$80.00 ➝ $160.00High
6/28/2021Truist SecuritiesBoost Price TargetBuy$80.00 ➝ $160.00High
6/28/2021WedbushBoost Price TargetNeutral$73.00 ➝ $87.00High
6/28/2021Roth CapitalBoost Price TargetBuy$80.00 ➝ $110.00High
6/28/2021The Goldman Sachs GroupBoost Price TargetBuy$115.00 ➝ $163.00High
6/28/2021BarclaysBoost Price TargetPositive ➝ Overweight$88.00 ➝ $134.00High
6/28/2021HC WainwrightBoost Price TargetBuy$111.00 ➝ $171.00High
6/26/2021Chardan CapitalBoost Price TargetBuy$85.00 ➝ $130.00High
6/23/2021Robert W. BairdBoost Price TargetPositive ➝ Neutral$60.00 ➝ $85.00High
6/23/2021JMP SecuritiesBoost Price TargetPositive ➝ Outperform$80.00 ➝ $88.00High
6/22/2021Jefferies Financial GroupBoost Price TargetBuy$83.00 ➝ $109.00High
6/22/2021HC WainwrightReiterated RatingBuy$111.00 ➝ $171.00Low
6/11/2021HC WainwrightInitiated CoverageBuy$111.00Medium
6/9/2021Raymond JamesReiterated RatingBuyLow
5/7/2021Roth CapitalUpgradeNeutral ➝ Buy$75.00 ➝ $80.00Medium
5/3/2021Royal Bank of CanadaInitiated CoverageOutperform$110.00Medium
3/21/2021SVB LeerinkReiterated RatingBuyHigh
3/4/2021JMP SecuritiesInitiated CoverageOutperform$80.00High
2/26/2021TruistBoost Price Target$40.00 ➝ $80.00High
2/10/2021Chardan CapitalBoost Price TargetBuy$57.50 ➝ $85.00Low
1/8/2021Raymond JamesBoost Price TargetOutperform$39.00 ➝ $106.00High
1/8/2021BarclaysBoost Price TargetOverweight$46.00 ➝ $90.00Low
12/22/2020Robert W. BairdDowngradeOutperform ➝ Neutral$60.00High
12/21/2020SVB LeerinkBoost Price TargetOutperform$27.00 ➝ $61.00High
12/7/2020Wells Fargo & CompanyBoost Price TargetOverweight$38.00 ➝ $52.00Medium
11/5/2020SVB LeerinkReiterated RatingOutperformMedium
10/27/2020TruistInitiated CoverageBuy$40.00 ➝ $40.00High
10/27/2020Summer StreetInitiated CoverageBuyHigh
10/19/2020Roth CapitalBoost Price TargetReduce ➝ Neutral$16.00 ➝ $26.00Low
10/14/2020Wells Fargo & CompanyInitiated CoverageOverweightMedium
9/30/2020OppenheimerReiterated RatingHoldHigh
9/18/2020The Goldman Sachs GroupInitiated CoverageBuy$33.00High
8/6/2020Chardan CapitalReiterated RatingBuyHigh
6/2/2020Credit Suisse GroupBoost Price TargetNeutral$19.00 ➝ $21.00High
6/1/2020WedbushBoost Price TargetNeutral$16.00 ➝ $20.00High
6/1/2020Chardan CapitalReiterated RatingBuy$57.50High
5/8/2020OppenheimerReiterated RatingHoldLow
4/2/2020BTIG ResearchReiterated RatingBuy$22.00Low
3/31/2020Chardan CapitalReiterated RatingBuy$57.50High
2/28/2020OppenheimerUpgradeMarket Perform ➝ OutperformHigh
2/14/2020WedbushDowngradeOutperform ➝ Neutral$21.00 ➝ $16.00High
2/10/2020Chardan CapitalReiterated RatingBuy$57.50Low
1/9/2020Chardan CapitalReiterated RatingBuy$57.50Medium
11/1/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$24.00High
9/27/2019Chardan CapitalSet Price TargetBuy$57.50High
7/8/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$23.00Medium
6/10/2019Roth CapitalInitiated CoverageNeutral$16.00High
5/28/2019Chardan CapitalReiterated RatingBuy$57.50Low
5/3/2019WedbushUpgradeNeutral ➝ Outperform$20.00 ➝ $21.00High
4/11/2019Evercore ISIInitiated CoverageOutperformHigh
2/27/2019Chardan CapitalReiterated RatingBuy$57.50High
2/7/2019BTIG ResearchInitiated CoverageBuy$20.00High
11/27/2018SVB LeerinkInitiated CoverageOutperform$23.00High
11/2/2018WedbushDowngradeOutperform ➝ Neutral$36.00 ➝ $20.00Medium
10/31/2018OppenheimerReiterated RatingHoldHigh
10/29/2018Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$24.00High
9/20/2018Raymond JamesInitiated CoverageMkt Perform ➝ Market PerformHigh
8/24/2018Chardan CapitalReiterated RatingBuy$57.50Low
5/18/2018WedbushReiterated RatingOutperform$36.00High
5/15/2018Chardan CapitalUpgradeNeutral ➝ BuyHigh
3/15/2018WedbushReiterated RatingOutperform$36.00High
3/14/2018SVB LeerinkReiterated RatingOutperformHigh
3/8/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ OutperformHigh
3/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$33.00 ➝ $46.00Medium
12/18/2017OppenheimerReiterated RatingHoldLow
12/12/2017OppenheimerReiterated RatingHoldHigh
11/5/2017BarclaysReiterated RatingBuyN/A
11/3/2017Credit Suisse GroupBoost Price TargetOutperform$24.00 ➝ $28.00N/A
10/31/2017Jefferies Financial GroupSet Price TargetBuy ➝ Buy$36.00 ➝ $42.00N/A
10/31/2017SVB LeerinkBoost Price TargetOutperform$29.00 ➝ $37.00N/A
10/3/2017Jefferies Financial GroupReiterated RatingBuy$36.00High
9/27/2017WedbushReiterated RatingOurperform$29.00 ➝ $25.00High
9/6/2017BarclaysInitiated CoverageOverweight$29.00Low
8/29/2017Chardan CapitalDowngradeBuy ➝ Neutral$20.00High
8/2/2017Chardan CapitalReiterated RatingBuy$19.00 ➝ $20.00Low
7/22/2017Jefferies Financial GroupReiterated RatingBuy$36.00High
7/18/2017OppenheimerInitiated CoverageMarket PerformHigh
6/22/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$36.00Low
6/3/2017Credit Suisse GroupSet Price TargetBuy$24.00Low
5/15/2017WedbushReiterated RatingOutperform$25.00High
5/3/2017Credit Suisse GroupSet Price TargetBuy$24.00Low
5/3/2017WedbushReiterated RatingOutperform$25.00High
3/27/2017Chardan CapitalInitiated CoverageBuy ➝ Buy$19.00Medium
3/14/2017WedbushReiterated RatingOutperform$25.00Low
2/16/2017WedbushReiterated RatingOutperform$25.00N/A
2/8/2017Jefferies Financial GroupReiterated RatingBuy$33.00N/A
1/11/2017Jefferies Financial GroupSet Price TargetBuy$33.00N/A
1/5/2017SVB LeerinkReiterated RatingOutperformN/A
12/12/2016Jefferies Financial GroupSet Price TargetBuy$33.00N/A
(Data available from 11/28/2016 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 6 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 6 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Intellia Therapeutics logo
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $113.13
Low: $111.01
High: $117.95

50 Day Range

MA: $132.89
Low: $113.13
High: $155.26

52 Week Range

Now: $113.13
Low: $35.61
High: $202.73


494,494 shs

Average Volume

1,493,221 shs

Market Capitalization

$8.31 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Intellia Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Intellia Therapeutics in the last year: Barclays PLC, Chardan Capital, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, Roth Capital, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist, Truist Securities, Wedbush, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for NTLA.

What is the current price target for Intellia Therapeutics?

18 Wall Street analysts have set twelve-month price targets for Intellia Therapeutics in the last year. Their average twelve-month price target is $146.28, suggesting a possible upside of 29.3%. The Goldman Sachs Group, Inc. has the highest price target set, predicting NTLA will reach $252.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $52.00 for Intellia Therapeutics in the next year.
View the latest price targets for NTLA.

What is the current consensus analyst rating for Intellia Therapeutics?

Intellia Therapeutics currently has 3 hold ratings and 15 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NTLA will outperform the market and that investors should add to their positions of Intellia Therapeutics.
View the latest ratings for NTLA.

What other companies compete with Intellia Therapeutics?

How do I contact Intellia Therapeutics' investor relations team?

Intellia Therapeutics' physical mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company's listed phone number is (857) 285-6200 and its investor relations email address is [email protected] The official website for Intellia Therapeutics is